FM
VRTX icon

Freemont Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Freemont Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,500
Closed -$2.9M – 125
2026
Q1 		$2.9M Sell
6,500
-700
-10% -$326K 0.44% 73
2025
Q4 		$3.26M Buy
7,200
+4,800
+200% +$2.07M 0.57% 49
2025
Q3 		$940K Sell
2,400
-17,600
-88% -$7.36M 0.47% 51
2025
Q2 		$8.9M Buy
20,000
+14,200
+245% +$6.54M 1.33% 25
2025
Q1 		$2.81M Sell
5,800
-600
-9% -$280K 0.92% 40
2024
Q4 		$2.58M Hold
6,400
– – 1.12% 29
2024
Q3 		$2.98M Hold
6,400
– – 1.46% 20
2024
Q2 		$3M Sell
6,400
-31,300
-83% -$13.6M 1.42% 14
2024
Q1 		$15.8M Sell
37,700
-11,700
-24% -$4.95M 2.25% 10
2023
Q4 		$20.1M Hold
49,400
– – 2.53% 11
2023
Q3 		$17.2M Sell
49,400
-8,300
-14% -$2.9M 2.57% 10
2023
Q2 		$20.3M Hold
57,700
– – 2.45% 9
2023
Q1 		$18.2M Hold
57,700
– – 2.55% 9
2022
Q4 		$16.7M Buy
57,700
+17,200
+42% +$5.24M 2.61% 9
2022
Q3 		$11.7M Buy
40,500
+19,700
+95% +$5.67M 2.14% 11
2022
Q2 		$5.86M Sell
20,800
-1,200
-5% -$321K 1.01% 40
2022
Q1 		$5.74M Buy
+22,000
New +$5.22M 0.87% 52
2021
Q3 		– Sell
-32,000
Closed -$6.25M – 116
2021
Q2 		$6.45M Hold
32,000
– – 0.93% 46
2021
Q1 		$6.88M Hold
32,000
– – 1.12% 43
2020
Q4 		$7.56M Buy
+32,000
New +$7.34M 1.41% 36

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Freemont Management's VRTX Position: Q2 2026 in Review

Freemont Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 6,500 shares — an estimated $2.9M sold.

Freemont Management first reported a position in VRTX in Q4 2020 and held it in 20 quarters. The position peaked at $20.3M in Q2 2023. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Freemont Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Freemont Management sold 6,500 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.9M.
  • Freemont Management first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 20 quarters.
  • Freemont Management's Vertex Pharmaceuticals position peaked at $20.3M in Q2 2023.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Freemont Management's 13F filing for Q2 2026, filed 11 Aug 2026.